temozolomide has been researched along with gemcitabine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Armand, JP | 1 |
| Patel, SR | 1 |
| Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E | 1 |
| Aragoncillo, P; Casado Herraez, A; Díaz-Rubio García, E; Gómez Díaz, R; Moreno Antón, F; Puente Vázquez, J | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Favaudon, V; Hennequin, C; Quero, L | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Hendzel, MJ; Kaufmann, SH; Patel, A; Poirier, GG; Rouleau, M | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Johnson, TD; Lawrence, TS; Lemasson, B; Leopold, JS; Li, F; Mikkelsen, T; Rehemtulla, A; Ross, BD; Williams, TM | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Courcelle, M; Djaker, N; Palama, T; Sahli, F; Savarin, P; Spadavecchia, J | 1 |
6 review(s) available for temozolomide and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
PARP inhibition: PARP1 and beyond.
Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Mice; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Substrate Specificity; Temozolomide | 2010 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
2 trial(s) available for temozolomide and gemcitabine
| Article | Year |
|---|---|
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Infusions, Intravenous; Liver; Lung; Male; Middle Aged; Remission Induction; Sarcoma; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
9 other study(ies) available for temozolomide and gemcitabine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Diagnostic Errors; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Ifosfamide; Kidney Neoplasms; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Taxoids; Temozolomide; Thoracic Surgery, Video-Assisted; Uterine Neoplasms | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherapy; Dacarbazine; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Drug Screening Assays, Antitumor; Gemcitabine; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Neoplasms, Experimental; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome; Tumor Burden | 2012 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Decitabine; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glioblastoma; Gold; Humans; Magnetic Resonance Spectroscopy; Metal Nanoparticles; Nanoconjugates; Proof of Concept Study; Spectrophotometry, Ultraviolet; Temozolomide | 2020 |